Advanced Search
Disease Phase
Title Drug
Clinical Trials Listing
  • < Previous
  • 1
  • Next >
  • Penn Treatment Trials (9)
  • Penn Non-Treatment Trials (7)
  • Phase 1: Solid Tumor Trials (0)
  • Proton Therapy Trials (0)
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-15410 A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia III Chemotherapy, Signal Transduction Inhibitor decitabine; sapacitabine
715 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101) III Immunotherapy Not Applicable
709 A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia III Bone Marrow Transplant / Stem Cell Transplant, Chemotherapy fludarabine; busulfan; melphalan; cyclophosphamide
UPCC 08412 Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen II Chemotherapy busulfan; clofarabine
SWOG-S0535 A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia II Chemotherapy, Complementary and Alternative Therapy, Immunotherapy arsenic trioxide; methotrexate; ATRA; gemtuzumab ozogamicin; mercaptopurine
UPCC 04407 A Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia II Antineoplastic Agent bexarotene
PrE0901 Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults With Acute Myeloid Leukemia (AML) in Complete Remission I / II Biological Therapy, Chemotherapy cytarabine; eltrombopag
PLX108-05 A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) I / II Signal Transduction Inhibitor PLX3397
UPCC 15411 A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia I / II Biological Therapy birinapant
Displaying: 1 - 9 of 9 Results
  • < Previous
  • 1
  • Next >